FDA authorizes new Eli Lilly monoclonal antibody duo From CNN Health’s Maggie Fox In this file photo, an employee at Eli Lilly works on an antibody treatment for Covid-19. Source: Eli Lilly The US Food and Drug Administration has granted emergency use authorization to a new version of Eli Lilly and Co’s antibody treatment for coronavirus that adds a second monoclonal antibody to one already authorized, the company said Tuesday. The new treatment adds etesevimab or LY-CoV016 to the already authorized bamlanivimab or LY-CoV555 to make a double-antibody version – one that might be more protective, the company says. Rival Regeneron has a dual antibody-cocktail on the market already.